The US Bankruptcy Court granted an order for the extension of the exclusivity periods for Pear Therapeutics, Inc. on February 12, 2024. As per the order, the debtor?s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 90 days i.e., up to May 6, 2024, and July 1, 2024, respectively.
Pear Therapeutics, Inc.
Equities
PEAR
US7047231052
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+19.41% | 45.51B | |
+38.65% | 38.13B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |